Navigation Links
Hospira Shares Results From Two Open-label Extension Studies for Biosimilar Infliximab in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
Date:10/31/2013

py; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.

Ulcerative colitis
Inflectra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Paediatric ulcerative colitis
Inflectra is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6‑MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

Ankylosing spondylitis
Inflectra is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

Psoriatic arthritis
Inflectra is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

Inflectra should be administered

  • in combination with methotrexate
  • or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.

Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X‑ray in patients with polyarticular symmetrical subtypes of the disease.

Psoriasis
Inflectra is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intole
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Hospira Unveils New Quality Laboratory and Investments at Rocky Mount, N.C., Plant
2. Hospira Launches Q Core Sapphire Infusion System in the United States
3. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
4. Hospira to Present at the Morgan Stanley Global Healthcare Conference
5. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
6. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
7. Hospira dévoile sa stratégie appareil mondiale
8. Hospira enthüllt weltweite Gerätestrategie
9. Hospira revela estrategia global para sus dispositivos
10. Hospira revela estratégia global para dispositivos
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... June 3 ViroPharma Incorporated (Nasdaq: VPHM ) today announced that ... the Jefferies 2010 Global Life Sciences Conference at 4:00 P.M. ET ... the Grand Hyatt in New York City . , ... Mr. Roberts also will present at the ThinkEquity Healthcare Conference ...
... , LOUISVILLE, Colo. , June 3 ... cost medical devices will be the topic of a breakout ... Conference and Exhibition. Corey Smith , executive director of ... "Your Mission: To Reduce Costs. Your Challenge: Control!" at ...
Cached Medicine Technology:ViroPharma to Participate in Two June Healthcare Investor Conferences 2Gaining Visibility and Control Over Purchases of Medical Devices is the Focus of a GHX Presentation at Premier Annual Breakthroughs Conference and Exhibition 2Gaining Visibility and Control Over Purchases of Medical Devices is the Focus of a GHX Presentation at Premier Annual Breakthroughs Conference and Exhibition 3
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... 19, 2014 Boston Scientific Corp. has ... ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go ... Liebhard LLP reports. According to a Motion ... company asserts that claims involving its Solyx pelvic mesh ... Remedies Code, a section of which shields manufacturers ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Pregnant women who ... premature or low birth weight babies, a new study suggests. ... Vancouver, Canada, and found that expectant mothers who lived in ... had a 20 percent lower risk of very preterm birth ... moderate preterm birth (30 to 36 weeks). Babies born ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Melanoma risk found to have genetic determinant 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Do Greener Neighborhoods Produce Healthier Babies? 2
... , SANTA ROSA, Calif., Sept. 21 Osseon ... cement delivery needle) and Osseoflex DR (steerable and curvable bone ... for marketing and clinical use in the European Union. , ... FDA approval in the United States, and allows for the ...
... , PEMBROKE, Bermuda, Sept. 21 ... announced today that Linda,McSmith, AVP, Risk Management for Allied World ... Allied World, at the Ohio Association of,Ambulatory Surgery Centers (OAASC) ... September 24-25, 2009. , Ms. McSmith,s ...
... , , , ... Inc. ("Astellas"), in partnership with the National Science Teachers Association ... science teachers to participate in the 2009 NSTA New Science ... to a range of tools and resources, while providing the ...
... , , PHILADELPHIA and LONDON, Sept. 21 ... that provides a unique combination of competitive intelligence and sales forecast ... of pipeline and marketed drugs . The product will be ... on October 8 and 9, and Bio Europe 2009 in Vienna ...
... N.C. The Defense Advanced Research Projects Agency (DARPA), the ... Duke University $19.5 million for an effort led by the ... a portable, easy-to-use diagnostic device that can reveal who is ... or sneeze. DARPA is interested in such a ...
... research and real world operation of electronic medical ... have developed, tested and are now operating innovative ... evidence-based medical information between clinical sources and public ... new tools developed by the Regenstrief Institute that ...
Cached Medicine News:Health News:Osseon Receives CE Mark 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 3Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 3Health News:Thomson Reuters Launches Thomson Pharma Partnering Forecast 2Health News:DARPA awards Duke $19.5 million to detect viral infection before symptoms appear 2Health News:Fighting disease outbreaks with 2-way health information exchange 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: